日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

针对 ESR1 激活突变的疫苗可引发抗肿瘤免疫反应并抑制对治疗有抵抗力的 ER+ 乳腺癌中的雌激素信号传导

Gabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C Hobeika, Amanda Summers, Robert D Marek, Michael A Morse, Herbert K Lyerly, Erika J Crosby, Zachary C Hartman

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

曲妥珠单抗/帕妥珠单抗联合疗法通过补体依赖性细胞毒性和吞噬作用刺激抗肿瘤反应。

Li-Chung Tsao ,Erika J Crosby ,Timothy N Trotter ,Junping Wei ,Tao Wang ,Xiao Yang ,Amanda N Summers ,Gangjun Lei ,Christopher A Rabiola ,Lewis A Chodosh ,William J Muller ,Herbert Kim Lyerly ,Zachary C Hartman

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

通过联合疫苗和 αPD-1 刺激致癌基因特异性肿瘤浸润 T 细胞,实现对已确诊的 HER2 乳腺癌的持续抗肿瘤反应

Erika J Crosby, Chaitanya R Acharya, Anthony-Fayez Haddad, Christopher A Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U Wagner, William J Muller, Lewis A Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H Shepherd, Daniel P Hollern, Xiaping He, Charles M Perou, Sh

CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis

CD47阻断增强曲妥珠单抗抗肿瘤疗效依赖于抗体依赖性细胞吞噬作用

Li-Chung Tsao ,Erika J Crosby ,Timothy N Trotter ,Pankaj Agarwal ,Bin-Jin Hwang ,Chaitanya Acharya ,Casey W Shuptrine ,Tao Wang ,Junping Wei ,Xiao Yang ,Gangjun Lei ,Cong-Xiao Liu ,Christopher A Rabiola ,Lewis A Chodosh ,William J Muller ,Herbert Kim Lyerly ,Zachary C Hartman